OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials.

A 54-year-old woman is found to have a skin lesion in the right arm. What is your diagnosis?

A novel immunotherapy antibody was safe and showed modest antitumor activity in a phase I clinical trial in advanced melanoma.

Objective tumor responses to pembrolizumab (Keytruda) and nivolumab (Opdivo) are associated with longer times between melanoma diagnosis and treatment.

An experimental checkpoint inhibitor called avelumab may produce quick and durable responses in some patients with metastatic Merkel cell carcinoma.

Researchers at Moffitt Cancer Center in Tampa, Fla., demonstrated how novel immune and targeted therapies with radiation therapy may improve the outcomes of patients with melanoma who have brain metastases.

Combining the BRAF inhibitor encorafenib with the MEK inhibitor binimetinib may significantly improve progression-free survival in BRAF mutant melanoma, according to a new phase III trial.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.